Literature DB >> 8361285

Hashimoto's thyroiditis and carcinoma of the thyroid: optimal management.

A P Sclafani1, M Valdes, H Cho.   

Abstract

Several authors have noted a high incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis (HT), and some have even considered HT a premalignant condition. The authors evaluated all patients with surgically proven HT at Beth Israel Medical Center in New York from 1985 through 1990. Of these 48 patients, 8 (17%) had thyroid carcinoma in addition to HT. No statistically significant difference between patients with and without concurrent carcinoma was noted in the percentage of patients with a dominant mass, irregular thyromegaly, compressive symptoms, suspicious fine needle aspiration biopsies (FNABs), or a cold nodule on thyroid scintigraphy. However, patients with neither a positive FNAB nor a cold nodule were much less likely to have carcinoma than patients with one or both of these tests positive (0% vs. 26%, P < or = .05). A management scheme for patients with HT is proposed to adequately and efficiently evaluate and treat patients for concurrent thyroid carcinoma.

Entities:  

Mesh:

Year:  1993        PMID: 8361285     DOI: 10.1288/00005537-199308000-00003

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  Hyperfunctioning differentiated thyroid carcinoma.

Authors:  M Appetecchia; M Ducci
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

2.  The reliability of fine-needle aspiration biopsy in terms of malignancy in patients with Hashimoto thyroiditis.

Authors:  Murat Kapan; Akin Onder; Sadullah Girgin; Burak Veli Ulger; Ugur Firat; Omer Uslukaya; Abdullah Oguz
Journal:  Int Surg       Date:  2015-02

3.  Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?

Authors:  Hee Yong Kwak; Byung Joo Chae; Yong Hwa Eom; Young Ran Hong; Jae Beom Seo; So Hee Lee; Byung Joo Song; Sang Seol Jung; Ja Seong Bae
Journal:  Int J Clin Oncol       Date:  2014-10-15       Impact factor: 3.402

4.  Demographic, clinical, laboratory, ultrasonographic, and cytological features of patients with Hashimoto's thyroiditis: results of a university hospital of 769 patients in Turkey.

Authors:  Mehmet Erdogan; Nihat Erdem; Sevki Cetinkalp; Ahmet Gokhan Ozgen; Fusun Saygılı; Candeger Yilmaz; Mehmet Tuzun; Taylan Kabalak
Journal:  Endocrine       Date:  2009-10-24       Impact factor: 3.633

5.  Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.

Authors:  C Mechler; A Bounacer; H Suarez; M Saint Frison; C Magois; G Aillet; A Gaulier
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

6.  Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto's thyroiditis.

Authors:  Aleksander Konturek; Marcin Barczyński; Wojciech Nowak; Wojciech Wierzchowski
Journal:  Langenbecks Arch Surg       Date:  2014-01-10       Impact factor: 3.445

7.  Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients.

Authors:  Christina Resende de Paiva; Christian Grønhøj; Ulla Feldt-Rasmussen; Christian von Buchwald
Journal:  Front Oncol       Date:  2017-04-10       Impact factor: 6.244

8.  Coexistence of papillary thyroid cancer with Hashimoto thyroiditis.

Authors:  Aleksander Konturek; Marcin Barczyński; Wojciech Wierzchowski; Małgorzata Stopa; Wojciech Nowak
Journal:  Langenbecks Arch Surg       Date:  2012-10-26       Impact factor: 3.445

9.  Thyroid papillary carcinoma associated to Hashimoto's thyroiditis.

Authors:  Luiz Alexandre Albuquerque Freixo Campos; Sílvia Miguéis Picado; André Vicente Guimarães; Daniel Araki Ribeiro; Rogério Aparecido Dedivitis
Journal:  Braz J Otorhinolaryngol       Date:  2012-12

10.  Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study.

Authors:  Y-K Chen; C-L Lin; F T-F Cheng; F-C Sung; C-H Kao
Journal:  Br J Cancer       Date:  2013-10-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.